Since 2008, we have founded and built 9 life science companies, a portfolio that is comprised of both established industry leaders and soon-to-be-known successes. With multiple patents, our companies have an aggregate market value of more than $400 million and have provided a 10x return to our early investors. And we are only getting started.
Medgenome is being India’s leading genomic diagnostics and research company which leverages South Asia’s unique founder populations to discover better diagnostics, screening tests and novel drug targets that address significant unmet needs across global markets.
Awarded MedTech Breakthrough award for biomedical research in 2018.
OncoPept is developing new therapies that empower the human immune system to beat cancer.
Ready to start two clinical trials.
Malignant Pleural Mesothelioma and HPV.
Head and Neck squamous cell carcinoma.
AgriGenome is being India’s leading plant and animal genomics company with 800+ research clients and a world-class seed development program.
Rice seed varieties that provide 25% more yield and 15-day decreased production cycle, is entering the regulatory approval process in 2019.
ModMab is leveraging the protein engineering revolution to develop new cancer medicines.
Modular Medically relevant antibody (ModMab) Therapeutics is a mid-stage drug development company with significant antibody drug candidate portfolio.
Emerge Biologics is believing that bio-betters can fill massive unmet patient and health system needs by accelerating the timelines for novel therapies, that act on known targets, to become available in emerging markets.